1.66 (10.39%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Neutral
Earnings
Very Weak
Earnings
Very Weak
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
Viridian Therapeutics, Inc.
Telephone
1.617.272.4600
Address
Suite 401, 221 Crescent Street, Waltham, MA 02453
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 12.8 - 34.29
Trade Value (12mth)
US$8,752,986.00
1 week
-5.05%
1 month
11.83%
YTD
-47.95%
1 year
16.91%
All time high
2247.75
EPS 3 yr Growth
-17.90%
EBITDA Margin
-511.30%
Operating Cashflow
-$277m
Free Cash Flow Return
-37.80%
ROIC
-38.50%
Interest Coverage
-73.20
Quick Ratio
12.60
Shares Outstanding (Fully Diluted)
102m
HALO Sector
Healthcare
Next Company Report Date
11-Mar-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 12 May 26 | |
| 12 May 26 | |
| 09 May 26 | |
| 09 May 26 | |
| 09 May 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | -5.31 | -3.07 | -3.32 | | | | ||
EPS (Fully Diluted) | $ | | | | | -5.31 | -3.07 | -3.32 | | | | ||
Growth | % | | | | | -31.2 | 42.2 | -8.2 | | | | ||
PE | X | | | | | N/A | N/A | N/A | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
